$6.84+0.09 (+1.33%)
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products.
Cumberland Pharmaceuticals Inc. in the Healthcare sector is trading at $6.84 with a market capitalization of $84M. The stock is currently near its 52-week high of $6.93, remaining 80.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.13Mβ | $13.68Mβ | $8.29Mβ | $10.84Mβ | $11.71M |
| Gross Profit | $7.20Mβ | $11.44Mβ | $7.30Mβ | $8.83Mβ | $10.29M |
| Operating Income | -$3.13Mβ | -$1.37Mβ | -$1.97Mβ | -$747,478β | $1.29M |
| Net Income | -$3.29Mβ | -$1.41Mβ | -$1.94Mβ | -$740,740β | $1.26M |
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Cal...
Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 2.2% and
Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 2.3% and the S
CPIX launches Vibativ in China through SciClone, expanding access to its antibiotic treatment for serious Gram-positive bacterial infections.
Alphabet, Apple and Micron lead Zacks analyst reports as AI demand and product cycles drive tech momentum.
Alphabet's AI-driven growth in Search, Cloud and subscriptions is boosting momentum, though spending and legal risks remain in focus.